Alkermes (ALKS) Change in Receivables (2010 - 2026)
Alkermes (ALKS) posted quarterly Change in Receivables of $48.8 million for Q2 2026, up 34.92% year-over-year from $36.2 million in Q2 2025, and up 110.4% quarter-over-quarter from $23.2 million in Q1 2026.
Alkermes (ALKS) Change in Receivables (2010 - 2026) Analysis & Trends
Alkermes (ALKS) has reported Change in Receivables for 17 consecutive years, with $48.8 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Change in Receivables rose 34.92% year-over-year to $48.8 million; the TTM figure through Jun 2026 stood at $51.2 million (up 544.7% YoY), while the FY2025 annual figure was -$50.5 million, down 197.02% from the prior year.
- Change in Receivables grew to $48.8 million in Q2 2026 per ALKS's latest filing, from $23.2 million in the prior quarter.
- Across five years, Change in Receivables topped out at $65.3 million in Q2 2023 and bottomed at -$65.8 million in Q1 2025.
- Historically, Change in Receivables has averaged $5.2 million across 5 years, with a median of $2.0 million in 2023.
- Annual changes were most pronounced in 2023 — Change in Receivables jumped 1695.8% — and 2025, when it tumbled 295.87%.
- Alkermes' Change in Receivables stood at $30.8 million in 2022, then tumbled by 116.95% to -$5.2 million in 2023, then surged by 431.76% to $17.3 million in 2024, then sank by 217.62% to -$20.4 million in 2025, then surged by 339.81% to $48.8 million in 2026.
- Business Quant data shows ALKS's Change in Receivables at $48.8 million in Q2 2026, $23.2 million in Q1 2026, and -$20.4 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 91.00 Mn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 66.00 Mn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | -445.26 Mn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | -1.70 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 126.50 Mn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 84.30 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Alkermes | 8.02 Bn | 7.37 Bn | 397.90 Mn | 48.85 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 48.85 Mn |
| Jun 30, 2026 | 48.85 Mn |
| Mar 31, 2026 | 23.22 Mn |
| Mar 31, 2026 | 23.22 Mn |
| Dec 31, 2025 | -20.37 Mn |
| Dec 31, 2025 | -20.37 Mn |
| Sep 30, 2025 | -512,000.00 |
| Sep 30, 2025 | -512,000.00 |
| Jun 30, 2025 | 36.20 Mn |
| Jun 30, 2025 | 36.20 Mn |
| Mar 31, 2025 | -65.83 Mn |
| Mar 31, 2025 | -65.83 Mn |
| Dec 31, 2024 | 17.32 Mn |
| Dec 31, 2024 | 17.32 Mn |
| Sep 30, 2024 | 795,000.00 |
| Sep 30, 2024 | 795,000.00 |
| Jun 30, 2024 | 50.57 Mn |
| Jun 30, 2024 | 50.57 Mn |
| Mar 31, 2024 | -16.63 Mn |
| Mar 31, 2024 | -16.63 Mn |